Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Henriette Farkas(Semmelweis University), William Sheridan(BioCryst Pharmaceuticals (United States)), Avner Reshef(Barzilai Medical Center), Sylvia Dobo(BioCryst Pharmaceuticals (United States)), Miloš Jeseňák(Martin University Hospital), Celia Zubrinich(Alfred Health), Enikő Nagy(BioCryst Pharmaceuticals (United States)), Anette Bygum(University of Southern Denmark), Aarnoud Huissoon(Heartlands Hospital), O. Fain(Sorbonne Université), Heather A. Iocca(BioCryst Pharmaceuticals (United States)), Sorena Kiani‐Alikhan(Royal Free London NHS Foundation Trust), Daniel Dix(BioCryst Pharmaceuticals (United States)), David Hagin(University of Washington), Vesna Grivcheva Panovska(Ss. Cyril and Methodius University in Skopje), Tamar Kinaciyan(Medical University of Vienna), Marcin Stobiecki(Jagiellonian University), Karen Lindsay(Auckland District Health Board), Urs C. Steiner(University of Zurich), Bhavisha Desai(BioCryst Pharmaceuticals (United States)), Emel Aygören‐Pürsün, Marcus Maurer(Charité - Universitätsmedizin Berlin), Jessica Best(BioCryst Pharmaceuticals (United States)), Adrian Wu(Center for Asthma, Allergy and Respiratory Disease), Melanie Cornpropst(BioCryst Pharmaceuticals (United States)), Sharon C. Murray(BioCryst Pharmaceuticals (United States)), Jonny Peter(University of Cape Town)
Clinical and Translational Allergy
June 1, 2021
Cited by 54


Related Papers